CanSino latest to file for HKEX IPO

Vaccines company CanSino Biologics Inc. (Tianjin, China) on Tuesday proposed to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by Morgan Stanley and CLSA. The news comes as multiple media outlets reported that Ascletis Pharma Inc. (Hangzhou, China), which proposed to list in May, set a price range for its IPO on the exchange.

CanSino said in its prospectus that it expects to submit an NDA for MCV4, a quadrivalent meningococcal conjugate vaccine, by year end as well as an NDA for MCV2, a bivalent meningococcal conjugate vaccine, MCV2 -- next year. The company did not say where it planned to make the regulatory submissions. The company's Ad5-EBOV, a recombinant human adenovirus type 5 vector based vaccine expression Ebola virus glycoprotein, is approved in China to treat Ebola virus infection...